tetano
Editor, Senior Moderator
Antiviral Res. 2017 Sep 20. pii: S0166-3542(17)30180-8. doi: 10.1016/j.antiviral.2017.09.009. [Epub ahead of print]
[h=1]Immune efficacy of an adenoviral vector-based swine influenza vaccine against antigenically distinct H1N1 strains in mice.[/h] Wu Y[SUP]1[/SUP], Yang D[SUP]2[/SUP], Xu B[SUP]2[/SUP], Liang W[SUP]2[/SUP], Sui J[SUP]2[/SUP], Chen Y[SUP]2[/SUP], Yang H[SUP]2[/SUP], Chen H[SUP]2[/SUP], Wei P[SUP]3[/SUP], Qiao C[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Avian-like H1N1 swine influenza viruses are prevalent in pigs and have occasionally crossed the species barrier and infected humans, which highlights the importance of preventing swine influenza. Human adenovirus serotype 5 (Ad5) has been tested in human influenza vaccine clinical trials and has exhibited a reliable safety profile. Here, we generated a replication-defective, recombinant adenovirus (designated as rAd5-avH1HA) expressing the hemagglutinin gene of an avian-like H1N1 virus (A/swine/Zhejiang/199/2013, ZJ/199/13). Using a BALB/c mouse model, we showed that a two-dose intramuscular administration of recombinant rAd5-avH1HA induced high levels of hemagglutination inhibition antibodies and prevented homologous H1N1 and heterologous H1N1 virus-induced weight loss, as well as viral replication in the nasal turbinates and lungs of mice. Furthermore, a prime-boost immunization strategy trial with a recombinant plasmid (designated as pCAGGS-HA) followed by rAd5-avH1HA vaccine provided effective protection against homologous and heterologous H1N1 virus infection in mice. These results indicate that rAd5-avH1HA is an efficacious genetically engineered vaccine candidate against H1N1 swine influenza. Future studies should examine its immune efficacy in pigs.
Copyright ? 2017. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Avian-like H1N1; Hemagglutinin; Protective immunity; Recombinant adenovirus; Swine influenza virus
PMID: 28941982 DOI: 10.1016/j.antiviral.2017.09.009
[h=1]Immune efficacy of an adenoviral vector-based swine influenza vaccine against antigenically distinct H1N1 strains in mice.[/h] Wu Y[SUP]1[/SUP], Yang D[SUP]2[/SUP], Xu B[SUP]2[/SUP], Liang W[SUP]2[/SUP], Sui J[SUP]2[/SUP], Chen Y[SUP]2[/SUP], Yang H[SUP]2[/SUP], Chen H[SUP]2[/SUP], Wei P[SUP]3[/SUP], Qiao C[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Avian-like H1N1 swine influenza viruses are prevalent in pigs and have occasionally crossed the species barrier and infected humans, which highlights the importance of preventing swine influenza. Human adenovirus serotype 5 (Ad5) has been tested in human influenza vaccine clinical trials and has exhibited a reliable safety profile. Here, we generated a replication-defective, recombinant adenovirus (designated as rAd5-avH1HA) expressing the hemagglutinin gene of an avian-like H1N1 virus (A/swine/Zhejiang/199/2013, ZJ/199/13). Using a BALB/c mouse model, we showed that a two-dose intramuscular administration of recombinant rAd5-avH1HA induced high levels of hemagglutination inhibition antibodies and prevented homologous H1N1 and heterologous H1N1 virus-induced weight loss, as well as viral replication in the nasal turbinates and lungs of mice. Furthermore, a prime-boost immunization strategy trial with a recombinant plasmid (designated as pCAGGS-HA) followed by rAd5-avH1HA vaccine provided effective protection against homologous and heterologous H1N1 virus infection in mice. These results indicate that rAd5-avH1HA is an efficacious genetically engineered vaccine candidate against H1N1 swine influenza. Future studies should examine its immune efficacy in pigs.
Copyright ? 2017. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Avian-like H1N1; Hemagglutinin; Protective immunity; Recombinant adenovirus; Swine influenza virus
PMID: 28941982 DOI: 10.1016/j.antiviral.2017.09.009